LYN and cancer: Due to the role of Lyn kinase in cancer, five Lyn inhibitors (Bosutinib, Ponatinib, Nintedanib, Dasatinib and Bafetinib) are used as therapeutics [26–32], with additional inhibitors, such as Saracatinib, currently in clinical trials [33].